JP6386585B2 - プロテインキナーゼのインヒビターとしてのフロピリジン - Google Patents

プロテインキナーゼのインヒビターとしてのフロピリジン Download PDF

Info

Publication number
JP6386585B2
JP6386585B2 JP2016565050A JP2016565050A JP6386585B2 JP 6386585 B2 JP6386585 B2 JP 6386585B2 JP 2016565050 A JP2016565050 A JP 2016565050A JP 2016565050 A JP2016565050 A JP 2016565050A JP 6386585 B2 JP6386585 B2 JP 6386585B2
Authority
JP
Japan
Prior art keywords
mmol
nmr
mhz
synthesis example
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016565050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513915A (ja
JP2017513915A5 (enExample
Inventor
パルッハ，カミル
ペトルヨヴァ，ミハエラ
ネメツ，ヴァツラフ
Original Assignee
マサリコヴァ ユニヴェルジタ
マサリコヴァ ユニヴェルジタ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マサリコヴァ ユニヴェルジタ, マサリコヴァ ユニヴェルジタ filed Critical マサリコヴァ ユニヴェルジタ
Publication of JP2017513915A publication Critical patent/JP2017513915A/ja
Publication of JP2017513915A5 publication Critical patent/JP2017513915A5/ja
Application granted granted Critical
Publication of JP6386585B2 publication Critical patent/JP6386585B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016565050A 2014-04-30 2015-04-29 プロテインキナーゼのインヒビターとしてのフロピリジン Active JP6386585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14166547.1 2014-04-30
EP14166547.1A EP2940022B1 (en) 2014-04-30 2014-04-30 Furopyridines as inhibitors of protein kinases
PCT/CZ2015/000038 WO2015165428A1 (en) 2014-04-30 2015-04-29 Furopyridines as inhibitors of protein kinases

Publications (3)

Publication Number Publication Date
JP2017513915A JP2017513915A (ja) 2017-06-01
JP2017513915A5 JP2017513915A5 (enExample) 2018-07-12
JP6386585B2 true JP6386585B2 (ja) 2018-09-05

Family

ID=50679866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565050A Active JP6386585B2 (ja) 2014-04-30 2015-04-29 プロテインキナーゼのインヒビターとしてのフロピリジン

Country Status (4)

Country Link
US (1) US9902733B2 (enExample)
EP (1) EP2940022B1 (enExample)
JP (1) JP6386585B2 (enExample)
WO (1) WO2015165428A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107216334A (zh) * 2017-06-29 2017-09-29 上海吉尔多肽有限公司 一种6‑氯呋喃[3,2‑b]吡啶的合成方法
US20250002507A1 (en) 2021-10-14 2025-01-02 Vanderbilt University 7,8-dihydro-5h-1,6-naphthyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4 for treating neurological and psychiatric disorders
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法
US20250304593A1 (en) * 2022-05-12 2025-10-02 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
EP4353727A1 (en) 2022-10-13 2024-04-17 Masarykova Univerzita Substituted furopyridines for therapeutic use
WO2024251187A1 (en) * 2023-06-06 2024-12-12 Beigene, Ltd. Benzofuran derivatives as sik inhibitors and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732969B1 (fr) * 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ333302A (en) 1996-08-28 2000-08-25 Pfizer Substituted 6,5-hetero-bicyclic derivatives for the prevention or inhibition of a disorder that can be treated by antagonising corticotropin releasing factor
US20010007867A1 (en) * 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2000050426A2 (en) * 1999-02-26 2000-08-31 Eli Lilly And Company Furo[3, 2-b]pyridines as 5-ht1f agonists
US6696439B1 (en) * 1999-02-26 2004-02-24 Eli Lilly And Company 5-HT1F agonists
AU2004270713A1 (en) * 2003-09-05 2005-03-17 Aventis Pharmaceuticals Inc. Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
WO2005023771A1 (ja) * 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
JP2007514731A (ja) * 2003-12-19 2007-06-07 ファイザー インコーポレイテッド 糖尿病及び肥満症の治療のための１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型（１１−β−ｈｓｄ−１）の阻害剤としてのベンゼンスルホニルアミノ−ピリジン−２−イル誘導体及び関連化合物
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8492378B2 (en) * 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
WO2011138657A1 (en) * 2010-05-04 2011-11-10 Glenmark Pharmaceuticals S.A. Aryl substituted olefinic compounds as pde10a inhibitors

Also Published As

Publication number Publication date
US20170037052A1 (en) 2017-02-09
JP2017513915A (ja) 2017-06-01
US9902733B2 (en) 2018-02-27
EP2940022A1 (en) 2015-11-04
EP2940022B1 (en) 2020-09-02
WO2015165428A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
JP6386585B2 (ja) プロテインキナーゼのインヒビターとしてのフロピリジン
US10000496B2 (en) Compositions useful for treating disorders related to kit and PDGFR
TWI662026B (zh) 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
TWI520962B (zh) As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
US9682967B2 (en) N-substituted-5-substituted phthalamic acids as sortilin inhibitors
JP6612857B2 (ja) ベンゾイミダゾールアナログおよび関連方法
WO2019134539A1 (zh) 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
KR20190086442A (ko) 피리딘 화합물
JP6820313B2 (ja) アミノナフトキノン化合物、および疾患におけるユビキチン化−プロテアソーム系をブロックするための薬学的組成物
KR20200055034A (ko) 키나아제 억제제로서의 시클릭 이미노피리미딘 유도체
JP2020527173A (ja) ヒストン脱アセチル化酵素１および／または２（ｈｄａｃ１−２）の選択的阻害剤としての新規なヘテロアリールアミド誘導体
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
CN110072526A (zh) 治疗癌症的激酶抑制剂化合物、组合物和方法
WO2016148114A1 (ja) 酸化ストレス誘導神経細胞死抑制化合物
US20230056497A1 (en) CD206 Modulators Their Use and Methods for Preparation
JP2022511236A (ja) 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用
WO2021041970A1 (en) Perk inhibiting imidazolopyrazine compounds
TW202204351A (zh) 具有大環結構的化合物及其用途
TWI691500B (zh) 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物
JP2018087173A (ja) 悪性脳腫瘍治療薬
JP2025525395A (ja) Ｄｙｒｋ／ｃｌｋの低分子阻害剤およびその使用
CN103906751A (zh) 作为晚期SV40因子（LSF）抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
CN117730083A (zh) 用作map4k1抑制剂的嘧啶化合物
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180123

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180523

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180731

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180809

R150 Certificate of patent or registration of utility model

Ref document number: 6386585

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250